Member news

New parliamentary scrutiny of the UK’s innovation landscape has reinforced longstanding concerns about how investment in innovation is distributed across the country, with Pioneer Group, a specialist in technology infrastructure and venture building, urging swift action to address persistent barriers to research commercialisation.

Sonjoy Brahma, tranScrip’s VP of Clinical Operations, joins Joab Williamson of Faron Pharmaceuticals to unpack the operational realities of life in a small emerging biotech. They’ll explore the pressures of rare oncology development, how cash runway and clinical milestones shape decision-making and why flexibility, external expertise and careful planning are essential to moving programmes forward with confidence.

Researchers have discovered a drug target that could potentially help tackle drug-resistant tuberculosis, one of the biggest causes of death worldwide.

The Modelling-Informed Medicine Centre (MiMeC) will provide a new UK hub for research in the emerging modelling-informed medicine field.

PIR International recently partnered with Gilgamesh Pharmaceuticals in appointing Bridget Walton as VP Regulatory Affairs.

Nominations were declared open today for the Life Sciences Week Awards - the climax of a national programme of health tech events launched in Birmingham, UK.

Quell announced last week that it has initiated the CHILL Phase 1/2 clinical study evaluating its QEL-005 CAR-Treg therapy in patients with Refractory Rheumatoid Arthritis and Systemic Sclerosis. Advancement of the program into clinical development follows the recent approval by UK MHRA of the company’s Clinical Trial Application (CTA). The CHILL clinical trial is a multinational basket study that will recruit participants in the UK, Germany and Spain. The trial is actively recruiting in the UK and early data are expected during Q1'27.

Free-to-attend conference takes place at AstraZeneca in Gothenburg, Sweden from 6-7 May

Poolbeg Pharma announces the appointment of Dr Adrian Kilcoyne to its Scientific Advisory Board.

Coulter Partners is pleased to announce the placement of David Rosenbaum, Ph.D. as Chief Development Officer (CDO).

Brainomix 360 Stroke has been deployed in all 25 sites, marking the first time the entire WVU network has access to a unified AI solution to support faster and more consistent acute stroke decision-making.

C‑Further launches its first targeted paediatric cancer programmes, collaborating with global academic and industry partners to advance new therapeutics.

Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, today announced that it has established a US subsidiary at The Engine in Cambridge, MA.

EnteroBiotix has completed enrolment in the Phase 2a MAST trial of EBX-102-02, investigating intestinal microbiota transplant prior to allogeneic stem cell transplantation in patients with haematological malignancies.

Glasgow’s newest purpose-built life sciences laboratory facility, the Health Innovation Hub (HiH), was officially opened by Wes Streeting, Secretary of State for Health and Social Care.

SignaCor Therapeutics has been named the winner of Discovery Park's startup growth programme for innovations in cardiovascular health, securing £250k in funding from venture capital firm Zinc.

Coulter Partners successfully led a search for Evondos Group to appoint Tom Ellison as Chief Financial Officer (CFO).

Outpost Bio has raised $3.5 million in pre-seed funding to build frontier AI models that make human microbiology computable, enabling more precise prediction and optimization of intervention outcomes.

Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon Europe 2025, the European Union’s flagship research and innovation funding programme.

Drug development consultancy Boyds has appointed Kate Owen as Medical Director in its Clinical and Medical Affairs team.